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Background: Diabetes–related lower limb amputations are associated with considerable morbidity and mortality
and are usually preceded by foot ulceration. The available systematic reviews of aggregate data are compromised
because the primary studies report both adjusted and unadjusted estimates. As adjusted meta-analyses of
aggregate data can be challenging, the best way to standardise the analytical approach is to conduct a meta-
analysis based on individual patient data (IPD).
There are however many challenges and fundamental methodological omissions are common; protocols are rare
and the assessment of the risk of bias arising from the conduct of individual studies is frequently not performed,
largely because of the absence of widely agreed criteria for assessing the risk of bias in this type of review. In this
protocol we propose key methodological approaches to underpin our IPD systematic review of prognostic factors
of foot ulceration in diabetes.
Review questions;
1.What are the most highly prognostic factors for foot ulceration (i.e. symptoms, signs, diagnostic tests) in people
with diabetes?
2.Can the data from each study be adjusted for a consistent set of adjustment factors?
3.Does the model accuracy change when patient populations are stratified according to demographic and/or
clinical characteristics?
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Methods: MEDLINE and EMBASE databases from their inception until early 2012 were searched and the
corresponding authors of all eligible primary studies invited to contribute their raw data. We developed relevant
quality assurance items likely to identify occasions when study validity may have been compromised from several
sources. A confidentiality agreement, arrangements for communication and reporting as well as ethical and
governance considerations are explained.
We have agreement from the corresponding authors of all studies which meet the eligibility criteria and they
collectively possess data from more than 17000 patients. We propose, as a provisional analysis plan, to use a multi-
level mixed model, using “study” as one of the levels. Such a model can also allow for the within-patient clustering
that occurs if a patient contributes data from both feet, although to aid interpretation, we prefer to use patients
rather than feet as the unit of analysis. We intend to only attempt this analysis if the results of the investigation of
heterogeneity do not rule it out and the model diagnostics are acceptable.
Discussion: This review is central to the development of a global evidence-based strategy for the risk assessment
of the foot in patients with diabetes, ensuring future recommendations are valid and can reliably inform
international clinical guidelines.Background
Diabetes–related lower limb amputations are associated
with considerable morbidity and mortality and are
usually preceded by foot ulceration. A recent analysis of
diabetes-related amputation rates in England found
there is a wide variation in incidence and researchers
suggest that this may be explained by a variation in the
delivery of care [1]. Annual assessment procedures are
recommended to identify those people with diabetes
who are at risk of foot ulceration [2-5] and there is some
evidence to support the use of certain diagnostic tests,
symptoms and signs but the role of other contributory
factors is less clear [6]. Currently there is insufficient
evidence that interventions to reduce foot amputations
or ulcerations are clinically or cost effective [7].
Meta-analyses based on aggregate data of independent
prognostic factors found the duration of diabetes, HbA1c,
Peak Plantar Pressure (PPP), and vibration perception
threshold (VPT) all distinguish between those people who
will develop a foot ulcer and those who will not. However,
there was significant heterogeneity between studies which
may be due to differences in lengths of follow-up, methods
of ascertaining the presence of ulcers and the use of differ-
ent cut-off points (thresholds) for some of the tests [6].
A systematic review of clinical prediction rules (CPRs)
for assessing the risk of developing diabetic foot ulceration
in people with diabetes identified five different risk stratifi-
cation tools derived from consensus amongst clinical
experts, literature reviews and prospective studies using
logistic regression methods [8]. The prognostic factors
were foot deformity, peripheral neuropathy, peripheral
vascular disease (pulses and/or ABI), and previous ampu-
tation, the presence of callus, the HbA1c, Tinea pedis, and
onymychosis. The review concludes that the CPR which
possesses the greatest accuracy continues to be the subject
of debate.Both reviews [6,8] found wide variations in the
estimates of the incidence of foot ulceration across
different study populations (2% to 17%) and as prediction
tools derived from high risk populations may be of less
value in the general diabetic population, this deserves
further consideration.
These systematic reviews represent the best attempts
to integrate evidence of prognostic factors to date, [6,8]
but the findings are compromised because authors of
some primary studies report adjusted estimates whilst
others report unadjusted estimates and it is unclear
whether the same confounders or effect modifiers have
been used. Conventional meta-analytic techniques using
data that have been estimated or averaged across all
individuals in a study - aggregate data - do not permit
adjustments for confounding to be performed and the
best way to reliably analyse data from several cohort
studies using a standard approach is to use individual
patient data (IPD) [9,10].
There are several advantages of IPD meta-analyses,
but the ability to conduct a more complete time-to
-event analysis, where outcomes can be adjusted for
prespecified covariates is key. We propose to conduct a
systematic review and meta-analysis of IPD to create a
statistical model of independent predicative factors of
diabetic foot ulceration [9-11].
A detailed assessment of 20 IPD articles conducted as
part of a synthesis of IPD reviews identified many
challenges associated with this research method and the
time-consuming and costly nature requires proper consid-
eration. Fundamental methodological omissions are com-
mon: the assessment of the risk of bias arising from the
conduct of individual studies is not usually performed and
a priori study protocols and ethics are rare [12].
Our protocol has been informed by this work and we
have identified 15 cohort studies through searches of
Crawford et al. BMC Medical Research Methodology 2013, 13:22 Page 3 of 7
http://www.biomedcentral.com/1471-2288/13/22electronic databases. These cohorts include data from
approximately 17,000 patients worldwide and the
authors of the original reports have agreed to collaborate
in this research by sharing data.
This review is central to the development of a global
evidence-based strategy for the risk assessment of the
foot in patients with diabetes, ensuring future valid
recommendations that can reliably inform international
clinical guidelines. A flow diagram of the stages involved
in a systematic review of IPD can be found in Additional
file 1: Appendix 1 [10].
Presentation of the hypothesis
Planned investigation
Research questions
 What are the most highly prognostic factors for
foot ulceration in people with diabetes (symptoms
signs, diagnostic tests and elements from the
patient history) based on IPD analysis?
 Can the data from each study be adjusted for a
consistent set of adjustment factors?
 Does the model accuracy change when patient
populations are stratified according to demographic
or clinical characteristics?
Testing the hypothesis and Implications of the
hypothesis
Planned investigation
Research objectives
We will systematically review cohort studies and include
individual patient data in a meta-analysis to estimate the
prognostic value of clinical characteristics and diagnostic
test results. This will allow us to develop a prognostic
model of the risk factors for diabetic foot ulceration
(DFU) based on data collected worldwide. We will test
the robustness of the model in different demographic
profiles – for example, age, duration of diabetes, control
of diabetes (insulin, diet or oral medication) and type of
diabetes (Type I, Type II).
Search method
The electronic search strategies used for in a previous
systematic review by members of our group will be
conducted according to the published methods [13].
Copies of the EMBASE and MEDLINE search strategies
can be found in Additional file 2: Appendix 2.
Selection criteria
One reviewer will apply the IPD review eligibility criteria
to the full-text articles of the studies identified in our lit-
erature search and also all studies excluded from our ag-
gregate systematic review to ensure we do not miss
eligible IPD. A second reviewer will apply the eligibilitycriteria to a 10% random sample of the abstract search
yield to check that no relevant material will be missed
by having only one reviewer assess all the abstracts.
Eligibility criteria
Types of Participants
The IPD review will only include data from individuals
who are free of foot ulceration at the time of study entry
and who have a diagnosis of diabetes mellitus (either
type 1 or type 2). Corresponding authors of all identified
cohort studies will be contacted and invited to share
their data. When we identify studies with patients who
had prevalent foot ulcers at the time of recruitment, we
will ascertain whether IPD are available for patients who
were free of ulceration at the time of recruitment.
Types of exposure variables
All elements from the patient history, symptoms, signs
and diagnostic test results will be considered for inclu-
sion in the prognostic model. These are collected vari-
ously as continuous, binary and multi-categorical data.
Type of outcome variable
The outcome variables will be incident foot ulceration
(present/absent) and time to ulceration from initial diag-
nosis of diabetes as well as from the time of screening.
Types of studies
We will seek data from all cohort studies which included
participants who were free of foot ulceration at the time
of study recruitment. Our previous work indicates that
data collected in older studies could be difficult to ob-
tain and we are aware that some investigators are no
longer in possession of their study data (Personal com-
munication, D. Armstrong 2012). Where data are un-
available, details of the study will be presented in
aggregate form in the final report.
Cohort studies which recruited patients with prevalent
and incident foot ulceration will be considered for inclu-
sion where it is possible to separate the data for these
patients.
Data extraction and quality assessment
Data extraction will be undertaken by 2 reviewers
working independently and disagreement will be
resolved by discussion. For quality assessment, a 2-stage
process will be used; 2 reviewers working independently
will complete those items available from the published
report together with information provided by authors of
the primary studies.
The assessment of methodological quality is an
important component of an IPD systematic review but
there is complexity in assessing potential threats to the
validity of primary studies for this research genre. No
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in aggregate systematic reviews of prognostic studies
[14] and there is a complete absence of established
guidelines for prognostic IPD reviews (personal commu-
nication, D. Altman, R.Riley 2012). Although flaws in the
recruitment of patients or the manner of data collection
can influence review findings, some domains usually
assessed by systematic reviewers of published reports are
irrelevant, e.g. those pertinent to the analysis performed
by the primary authors. We have compiled a list of items
relevant to our IPD review question which are likely to
identify studies with data which are compromised by
threats of validity. This checklist of items can be found
in Additional file 3: Appendix 3 [15-26], it has been
refined during a pilot phase by 2 researchers working
independently.
Heterogeneity
As with any meta-analysis, heterogeneity must be
considered, both from a clinical and statistical viewpoint.
First, clinical expertise will be used to decide if it would
be meaningful to combine the studies based on the pa-
tient demographics, risk factors (symptoms, signs and
diagnostic test results), outcome measures and timing of
outcome measures (length of follow-up). We will exam-
ine histograms of relevant variables from each dataset to
check the spread, mean, median, and skewedness, and
the consistency of these properties across datasets, be-
fore reaching a decision about whether it makes clinical
or statistical sense to combine the data. We will also
consider relationships between variables using tables and
scatter plots.
Sources of heterogeneity that particularly concern us
are differences between the patient groups with regard
to basic demographics and disease spectrum as these
may have a strong influence on prognosis and the
performance of the tests. Also important are the various
methods used to conduct the tests, which again may
lead to marked differences in test performance. Another
potentially important source of heterogeneity is length
of follow-up as this may impact on the proportion of
patients who develop ulceration. These aspects will be
carefully detailed during the review process.
We are aware that a consensus has not yet been
reached about the investigation of heterogeneity in IPD
systematic reviews. Therefore we will use conventional
methods of investigating heterogeneity on aggregate data
generated from the datasets. We shall therefore generate
summary measures and use these to create forest plots
and compute I [2] statistics [27]. I [2] values of 50% and
75% have been used to denote moderate and high levels
of variation between studies that are not explainable by
chance. We shall use these figures as a guide only,
together with the results from the IPD [28].Statistical analysis
We propose to use a multi-level mixed model, using
“study” as one of the levels. Such a model can also allow
for the within-patient clustering that occurs if a patient
contributes data from both feet, although to aid inter-
pretation, we prefer to use patients rather than feet as
the unit of analysis. We will only attempt this analysis if
the results of the investigation of heterogeneity do not
rule it out and the model diagnostics are acceptable.
As the datasets should contain the date of initial diagno-
sis of diabetes and the date, if any, of foot ulceration, we
propose to use survival analysis. Covariates will be added
to the model based on clinical relevance, if there are many
possible covariates that could be added given the number
of events and patients and there is a danger of model over-
fitting, the clinicians will be asked to choose a subset of
covariates based on their expertise and experience. We
shall not use data-derived methods as these lead to overly
optimistic estimates of model performance. Model per-
formance will be assessed graphically and with chi-square
and other goodness-of-fit statistics.
As we plan to use the patient, rather than the foot, as
the unit-of-analysis, we can use a simpler model that will
be easier to interpret. It is also important from the view
of patient outcomes – an amputation affects the patient
as a whole and not just the foot. One approach to con-
struct the model is to use the most badly affected foot
from each patient. However, if the model performance
merits an analysis using the foot as the unit-of-analysis,
and of course allowing for the correlation between feet
belonging to the same patient, we shall conduct such
an analysis.
To avoid a loss of information, wherever possible we
shall keep continuous variables as continuous and not
dichotomise or otherwise categorised variables, e.g. we
shall use BMI, rather than subdivide patients into
“underweight”, “normal weight”, “overweight”, and “obese”.
Sometimes the relationship between a continuous covariate
and the outcome is not linear, and in such cases we will
investigate the use of fractional polynomials and similar.
Validation of the dataset
We intend to undertake both internal and external valid-
ation of the prognostic model. For internal validation,
we will not divide the datasets into development and
validation subsets, as this is a relatively inefficient
method of validating prediction models. Instead we shall
use bootstrapping as it is less susceptible to bias and
leads to more stable model development [28]. For
external validation, we shall reserve one or two of the
datasets to test the final model obtained in the main
analyses. The reserved datasets will be chosen on the
basis of completeness of variables collected so that, we
hope, all the variables present in the final model will also
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modification of the final model for external validation
purposes. We also shall look at various characteristics of
each dataset such as patient demographics when choosing
the reserve datasets to ensure that these datasets are not
atypical of the set of datasets.
Unfortunately we are currently lacking the data required
for a full power calculation. However, as an illustration, as-
suming that it is possible to split the sample of 17000 evenly
in half into patients with and without some prognostic fac-
tor, it would be possible to detect a 2% difference in the
proportions of patients with foot ulcers in each group with
over 90% power. This calculation assumes that the ulcer-
ation rate in one group is 0.10 and 0.08 in the other. With a
Type I error rate of 0.05, these figures give a power of
99.53%.
Handling missing data
Our method for handling missing data will depend on
the extent of the missingness and if the mechanism
causing the missingness is known, specifically if they are
missing completely at random, or not. If the datasets
contain missing data for which there is no explanation,
they will be assumed to be ‘missing at random [29].
We will use ICE multiple imputation (ICE programs,
Stata 11.0) [30], and include all available patient
variables (including the patient outcome: foot ulceration)
in the imputation model to help predict missing data for
the variables of interest. Twenty imputed datasets will
be used and included in the imputation procedure. To
test the validity of the imputation, a sensitivity analyses
will be performed restricting our cohort to patients
without missing data (complete case analysis) [31].
Specifying variables for analysis
A full list of the most common variables reported in cohort
studies is presented in Additional file 4: Appendix 4.
Examples of variables of interest are below. Importantly the
dates relating to patient recruitment, the timing of the
measurement of variables and the date of follow-up are also
required.
Continuous variables (and date measured)
1. Age
2. BMI
3. HbA1c
4. ABI
5. Peak plantar pressure (PPP)
6. Duration of diabetes
Binary and other categorical variables (and date measured)
1. Gender
2. Cutaneous sensation (monofilaments)3. Vibration Perception Thresholds (VPT (tuning forks
and neuro or biothesiometers))
4. Absent pedal pulses
5. Diabetes-related medication use
Outcome variable; Incident foot ulceration (present/
absent) and time to ulceration (date measured).
Supplying the data
The authors of the cohort studies will be able to supply
data in any way that is most convenient to them. A
single individual will be identified for each study to
whom all queries about the data collection processes
and transformation of individual variables will be
addressed. The research committee structures can be
found in Additional file 4: Appendix 4.
Ethics and governance
The ethics of obtaining data collected from a number of
sources which cross international boundaries and different
legal systems have been carefully considered and informed
by ethics advice issued by the Medical Research Council
(UK). This study does not require separate ethical commit-
tee approval for the following reasons;
 Investigators of each of the original studies obtained
local ethical committee approval and written,
informed patient consent prior for each of the
cohorts included in the IPD review.
 The project seeks anonymised data from which the
individuals recruited to the original study cannot be
identified [32].
The value of the IPD analysis will be the production of
a global dataset of prognostic factors for diabetic foot
disease and the opportunities for new uses will be
maximised. Anonymised data from each of the
collaborators of the primary cohort studies will be
transported in a manner deemed most convenient to
original study investigators including encrypted USB
sticks if required.
Data will then be formatted in a consistent way to
permit a re-analysis. Data will be stored in password
protected files on a secure University of Edinburgh
computer [University of Edinburgh Data protection
registration number: [Z6426984]] and will only be
accessible by a member of the Data Management
Committee, membership of which can be found in
the appendices.
This protocol incorporates a data confidentiality agree-
ment which makes clear the need for the data provided to
de-identify individual patients. It also includes an assurance
that the original investigators are in possession of local
ethical approval for their study.
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Regular e-mail updates will be used to inform the inter-
national group of our activities. Electronic media such as
Drop Box and e-mail may be used to store and exchange
data and paperwork between the original investigators
and the researchers. When researchers are cleaning a
specific data set they may communicate with the original
investigators via telephone discussions or by email.
Collaborators face to face meeting
Once the initial analysis has been performed, a face-to-face
meeting of all collaborators will be convened. The purpose
of the meeting is to allow the collaborators know the
results of the review and meta-analysis first and to have
the opportunity to interpret the data and question the
findings Additional file 5: Appendix 5 and Additional file 6:
Appendix 6.
Reporting
In the final report we will clearly present the methods of
the review such as tabulated characteristics of included
studies and details of study designs. The report will
conform to recommendations in the PRISMA checklist.
Formal synthesis of the results and formal assessments
of study quality will also be presented [33].
This protocol is registered with PROSPERO (Inter-
national Prospective Register of Systematic Reviews) at
the NHS Centre for Reviews and Dissemination (CRD)
at the University of York [34]. [Registration number:
CRD42011001841].
Public Partners Involvement (PPI)
The research is supported by a public partner from
Diabetes UK who ensures the research incorporates
aspects of risk assessment that matter to patients. His
views, opinions and perspective have ensured the study
documentation and data collection processes are acceptable
to the general diabetic population.Additional files
Additional file 1: Appendix 1. Flow diagram of the stages in an IPD
review adapted from Stewart and Clark 199510.
Additional file 2: Appendix 2. Embase and MEDLINE searches.
Additional file 3: Appendix 3. Questionnaire to determine the
methodological standards adopted in cohort studies evaluating the
prognostic factors for foot ulceration in diabetes.
Additional file 4: Appendix 4. List of the most common variables
reported in cohort studies.
Additional file 5: Appendix 5. Committees and members.
Additional file 6: Appendix 6. Data agreement for the collaborators.
Competing interests
The authors have no financial competing interests.Authors’ contributions
FC is the Chief Investigator, and GDM the Principal Investigator with overall
responsibility for the statistical analysis, together with CA and FMC they form
the Data Management Committee and have day to day responsibility for the
research. Together with JFP, AS,CRS, GPS,MJY and MM they form the
research steering committee each of whom are co-investigators and have
contributed to the design and writing of the research protocol. CAA,AJMB,
EJB,TK,GPL,MM,MM-S,SJR-N,AV are the principal investigators/corresponding
authors on all cohort studies identified by the review search strategy. They
have contributed individual patient data to the meta analysis. Together with
the Research Steering Committee and the independent advisors they form
the international steering committee work closely with members of the data
management committee in the preparation of the data. NC,WJJ,NL,TF,JT are
the project independent advisors who make clinical and methodological
contributions. They have collaborators status and are members of the
International Steering committee. All authors read approved the final
manuscript.
Research funding
This project was funded by the National Institute for Health Research Health
Technology Assessment (NIHR HTA) Programme (project number 10/57/08)
and will be published in full in Health Technology Assessment.
The views and opinions expressed therein are those of the authors and do
not necessarily reflect those of the HTA programme, NIHR, NHS or the
Department of Health.
Author details
1Department of vascular Surgery, Freeman Hospital, Newcastle upon Tyne
Hospitals NHS Foundation Trust, High Heaton, Newcastle NE7 7DN, UK.
2Centre for Population Health Sciences, Medical School, The University of
Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK. 3School of Surgical &
Reproductive Sciences, 3rd Floor, William Leech Building, Faculty of Medical
Sciences, Framlington Place, Newcastle upon Tyne NE2 4HH, UK.
4Department of Diabetes, Royal Infirmary of Edinburgh, 51 Little France
Crescent, Old Dalkeith Road, Edinburgh EH16 4SA, UK. 5Centre for
Endocrinology & Diabetes, Institute of Human Development, Core
Technology Facility, room 3.30, University of Manchester, 46 Grafton Street,
Manchester M13 9NT, UK. 6Manchester Royal Infirmary, Division of Medicine,
Oxford Road, Manchester M13 9WL, UK. 7Epidemiologic Research and
Information Center, VA Puget Sound Health Care System, University of
Washington, 1100 Olive Way, Suite 1400, Seattle, WA 98101, USA. 8Science
Consulting & Clinical Monitoring SCCM, Hessegasse 30/15, Wien A-1220,
Australia. 9Department of Diabetes and Endocrinology, Ninewells Hospital
and Medical School, Dundee DD1 9SY, UK. 10Medico dirigente I livello,
Sezione diabetologia, Cardiologia Geriatrica, AOU Careggi, Florence, Italy.
11Serviço de Endocrinologia–Pé Diabético, Centro Hospitalar de Vila Nova de
Gaia/Espinho EPE, Unidade 1, Rua Conceição Fernandes, Vila Nova de Gaia
4434-502, Portugal. 12Cass Lake Indian Health Services Hospital, 425 7th St
NW, Cass Lake MN 56633, USA. 13Harvard Medical School, 1563 Mass. Ave #
324, Cambridge, MA 02138, USA. 14Newcastle hospitals community health,
Podiatry Department, Geoffrey Rhodes clinic, Algernon Road, Byker,
Newcastle upon Tyne NE6 2UZ, UK. 15Department of Diabetes and
Endocrinology, Nottingham City Hospital, Hucknall Road, Nottingham NG5
1PB, UK. 16Ward 31, Royal Victoria Hospital, Newcastle NE1 4LP, UK. 17Royal
College of Surgeons in Ireland, 123 St Stephens Green, Dublin 2, Ireland.
18MRC Clinical Trials Unit, Aviation House, 125 Kingsway, London WC2B 6NH,
UK.
Received: 30 December 2012 Accepted: 17 January 2013
Published: 15 February 2013
References
1. Holman N, Young RJ, Jeffcoate WJ: Variation in the recorded incidence of
amputation of the lower limb in England. Diabetologia 2012, 55(7):1919–25.
2. General Medical Services Contract. http://www.nice.org.uk/aboutnice/qof/
indicators_detail.jsp?summary=13080 Checked 24/04/2011.
3. McIntosh A, Peters J, Young R: Prevention and management of foot problems
in type 2 diabetes: clinical guidelines and evidence. Sheffield: Sheffield
University; 2003. NICE guideline.
4. The International consensus on the diabetic foot. In International concensus on
the diabetic foot. 2012. http://iwgdf.org/ [accessed 28/09/2012.
Crawford et al. BMC Medical Research Methodology 2013, 13:22 Page 7 of 7
http://www.biomedcentral.com/1471-2288/13/225. Scottish Intercollegiate Guideline Network: The Management of Diabetes. A
National Clinical Guideline (No 116) ISBN 978 1 905813 58 2. March 2010. http://
www.sign.ac.uk/guidelines/fulltext/116/index.html (accessed 22/01/2013).
6. Crawford F, Inkster M, Kleijnen J, Fahey T: Predicting foot ulcers in patients
with diabetes: a systematic review and meta-analysis. Q J Med 2007,
100(2):65–86.
7. Dorresteijn JAN, Kriegsman DMW, Valk GD: Complex interventions for
preventing diabetic foot ulceration. Cochrane Database Syst Rev 2010, (1):
CD007610. doi:10.1002/14651858.CD007610.pub2.
8. Monteiro-Soares M, Boyko EJ, Ribeiro J, Ribeiro I, Dinis-Ribeiro M: Risk
stratification systems for diabetic foot ulcers: a systematic review.
Diabetologia 2011, 54(5):1190–1199.
9. Riley RD, Lambert PC, Abo-Zaid G: Meta-analysis of individual participant
data: rationale, conduct, and reporting. BMJ 2010, 340:c221.
10. Stewart LA, Clarke MJ: Practical methodology of meta-analyses
(overviews) using updated individual patient data. Cochrane Working
Group. Stat Med 1995, 14(19):2057–2079.
11. Clark MJ, Stewart LA: Obtaining individual patient data from randomised
controlled trials. In Systematic Reviews In Health Care, Meta analysis in
context. Edited by Egger M, Davey-Smith GD, Altman DG. London: BMJ
Books; 2001.
12. Abo-Zaid G, Sauerbrei W, Riley RD: Individual participant data meta-
analysis of prognostic factor studies: state of the art? BMC Med Res
Methodol 2012, 12(1):56.
13. Lefebvre C, Manheimer E, Glanville J: Chapter 6 Searching for studies. In
Edited by Higgins JPT, Green S. http://www.crd.york.ac.uk/prospero/
accessed 22/01/13.
14. Hayden JA, Pierre Cote DC, Bombardier C: Evaluation of the quality of
prognostic studies in systematic reviews. Ann Intern Med 2006, 144:427–437.
15. Crombie IK: The Pocket Guide to Critical Appraisal. London: BMJ publishing
group; 1996.
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M: Clark GM for the
statistics subcommittee of the NCI-EORTC working group on cancer
diagnostics. J Natl Cancer Inst 2005, 97(16):1180–1184.
17. Altman DG, Lyman GH: Methodological challenges in the evaluation of
prognostic factors in breast cancer. Breast Cancer Res Tr 1998, 52:289–303.
18. Rector T, Taylor BC, Wilt TJ: Chapter 12: systematic review of prognostic
tests. J Gen Int Med 2012, 27(suppl):S94–S101.
19. Altman DG: Systematic reviews of evaluations of prognostic variables.
BMJ 2001, 323(7306):224–228.
20. Laupacis A, Sekar N, Stiell IG: Clinical prediction rules. A review and
suggested modifications of methodological standards. J Am Med Assoc
1997, 277(6):488–494.
21. Wasson JH, Sox HC, Neff RK, Goldman L: Clinical prediction rules.
Applications and methodological standards. New Engl J Med 1985,
313(13):793–799.
22. Fowkes FRG, Fulton PM: Critical Appraisal of published research,
introductory guidelines. BMJ 1991, 302:1136–1140.
23. Vandenbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock
SJ, et al: Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007,
4(10):e297.
24. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke
JP: The Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) statement: guidelines for reporting
observational studies. J Clin Epidemiol 2008, 61(4):344–349.
25. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB,
Leeflang MMG, Sterne AV, Bossuyt PMM: QUADAS-2: A revised tool for the
quality assessment of diagnostic accuracy studies. Ann Intern Med 2011,
155-529-536.
26. Stroup DF, Berlin JA, Morton SC, Ingram O, Williamson CD, Rennie D, Moher
D, Becker BJ, Sipe TA, Thaker SB: For the meta analysis of observaltional
studies in epidemiology (MOOSE) group. Meta analysis of observational
studies in epidemiology. JAMA 2000, 283(15):2008–12.
27. Systematic reviews: CRDs Guidance for undertaking reviews in health care.
The University of York; 2008. http://www.york.ac.uk/inst/crd/index_guidance.
htm Accessed.
28. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis.
Stat Med 2002, 21(11):1539–155827.
29. Royston P: Multiple imputation of missing values: update. Stata J 2005,
5:188–201.30. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al:
Multiple imputation for missing data in epidemiological and clinical
research: potential and pitfalls. BMJ 2009, 338:b2393.
31. Steyerberg EW: Validation of prediction models. In Clinical Prediction Models.
A practical approach to development, validation and updating. US: Springer;
2009.
32. Medical Research Council (MRC) Ethics Series: Personal Information in
Medical Research. www.mrc.ac.uk (accessed 14th May 2012).
33. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Int
Med 2009, 151(4):264–9. W64.
34. PROSPERO: International Prospective Register of Systematic Reviews. NHS
National Institute of Health; 2012.
doi:10.1186/1471-2288-13-22
Cite this article as: Crawford et al.: Protocol for a systematic review and
individual patient data meta-analysis of prognostic factors of foot
ulceration in people with diabetes: the international research
collaboration for the prediction of diabetic foot ulcerations (PODUS).
BMC Medical Research Methodology 2013 13:22.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
